Post-COVID-19 hematologic complications: a systematic review

Alahyari, Sam; Moradi, Milad; Rajaeinejad, Mohsen; Jalaeikhoo, Hasan

doi:10.1080/17474086.2022.2080051

Cited by 11 publications

(8 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,4 COVID-19 is associated with a hypercoagulable state and resulting thromboembolic events, including deep vein thrombosis, pulmonary embolism, and stroke. [4][5][6][7] Several mechanisms have been proposed including endothelial injury, inflammation, complement activation, and deactivation of antithrombotic pathways. 8 An interesting model, based off postmortem studies and these mechanisms, postulates that injury to the lung tri-compartment (pulmonary artery, bronchial artery, and alveolus) leads to pulmonary vein thrombosis and subsequent large vessel occlusion (LVO) 9 .…”

Section: Introductionmentioning

confidence: 99%

Patients with COVID-19 Infection and Stroke have Higher than Expected Mortality, Regardless of the Primary Presentation

Liu,

Fu,

Gillette

et al. 2024

Preprint

View full text Add to dashboard Cite

Background COVID-19 infection is associated with thrombotic events; however, this phenomenon is poorly understood. Few studies have reported the association between COVID-19 and stroke in the hospital setting. Methods We retrospectively reviewed and characterized all patients who presented to a single, quaternary medical center between March and December 2020 (N=603). COVID-19 positive patients who developed ischemic or hemorrhagic stroke were included in the analysis (N=66). This cohort was compared with patients who were COVID-19 negative at the time of stroke presentation in the same period (N=537). Statistical significance was evaluated using Pearson's Chi squared test with Yates' continuity correction and linear model ANOVA. Results Sixty-six patients had COVID-19 and Stroke. Of these patients, 22 (33.4%) patients initially presented with stroke and 44 (66.7%) initially presented with COVID-19. Patients who presented with COVID-19 and had a stroke during their hospitalization (COVID-first) had worse outcomes than patients presenting to the hospital with stroke whose COVID test became positive later in the hospitalization (stroke-first). Patients who presented with COVID-19 and had a stroke during their hospitalization had an increased rate of acute renal failure (48.9% vs 19.0%, p=0.021) and need for ventilation (60.0% vs 28.6%, p=0.017). Further, in the COVID-first cohort, the use of heparin prior to the stroke event was not associated with mortality or type of stroke (ischemic or hemorrhagic). Conclusion In the early pandemic, patients with COVID-19 infection and stroke had a higher mortality rate compared to COVID-19 negative patients with stroke. Among patients with both COVID-19 and stroke, patients presenting with COVID-19 first had worse outcomes than patients presenting with stroke first. The use of heparin prior to the stroke event was not associated with mortality or type of stroke.

show abstract

Section: Introductionmentioning

confidence: 99%

Patients with COVID-19 Infection and Stroke have Higher than Expected Mortality, Regardless of the Primary Presentation

Liu,

Fu,

Gillette

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The global pandemic of COVID-19, with more than 600 million confirmed cases worldwide, is associated with varying severity of presentation and complications. Understanding of the nature of COVID-19 disease is still evolving [7][8][9][10]. There are a few reported cases of COVID-19 with G6PD deficiency who were found to have simultaneous hemolytic anemia and methemoglobinemia.…”

Section: Introductionmentioning

confidence: 99%

Co-Occurring Hemolysis and Methemoglobinemia After COVID-19 Infection in Patient With G6PD Deficiency

Malakah¹,

Baghlaf²,

Alsulami³

2023

Cureus

View full text Add to dashboard Cite

Hemolytic anemia and methemoglobinemia are known complications in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. They can be elicited by various oxidative stressors.Here we report a case of an adult with the first episode of G6PD deficiency associated hemolysis and methemoglobinemia after acquiring COVID-19 infection, who had no recent exposure to oxidative drugs or fava beans. A 52-year-old gentleman known to have myocardial bridging on aspirin and beta-blocker, with no other medical illnesses, developed anemia symptoms, jaundice, and hypoxia after contracting COVID-19 infection. Further laboratory work revealed non-immune hemolytic anemia, methemoglobinemia, and a positive G6PD screen test. He was treated conservatively with a blood transfusion, and his oxygen saturation improved thereafter.With the widespread COVID-19 infection and its morbidity worldwide, it is crucial to consider methemoglobinemia in the differential diagnosis of hypoxia. Testing for G6PD is an essential next step in such cases, as starting methylene blue in G6PD deficiency can worsen hemolysis. Apart from COVID-19, there is no other identified trigger for the acute event in this patient. It is not known whether COVID-19 infection alone is enough to result in G6PD deficiency-associated hemolysis and methemoglobinemia simultaneously.

show abstract

“…3, 4 This condition can be triggered by various inflammatory factors, such as infections or vaccinations, 5 and has been further complicated by the global COVID-19 crisis. 6–8 This has raised concerns about the potential adverse effects of COVID-19 vaccination in individuals with ITP. 9, 10…”

Section: Introductionmentioning

confidence: 99%

The impact of COVID-19 vaccines on patients with immune thrombocytopenic purpura: A protocol for a systematic review and meta-analysis

Li,

Kong,

Ding

et al. 2023

Preprint

View full text Add to dashboard Cite

IntroductionImmune thrombocytopenic purpura (ITP) is characterized by a decrease in platelet counts and can be triggered by various factors, such as viral infections and vaccinations. Concerns have emerged regarding potential links between the vaccines for COVID-19 and the worsening of ITP. This systematic review aims to comprehensively assess the impact of COVID-19 vaccines on patients with ITP, including associated risks and outcomes.Methods and AnalysisA thorough search will be conducted across multiple electronic databases, including PubMed, Web of Science, EMBASE, Cochrane Library, CNKI, Wan Fang, VIP, and CBM, to identify pertinent studies. This study will encompass randomized controlled trials, cohort studies, case-control studies, and case series that assess the effects of COVID-19 vaccines on individuals with ITP. The primary outcome will center on alterations in platelet count, while secondary outcomes will encompass the occurrence of thromboembolic events, bleeding complications, recurrence rate of ITP, impact of ITP exacerbation, and adverse events. The data will be synthesized and subjected to meta-analysis using Review Manager Software (RevMan) V.5.3. Additionally, subgroup analyses will be conducted to investigate potential sources of heterogeneity.Ethics and disseminationSince this study involves the analysis of previously published data, ethical approval is not required. The findings will be disseminated through publication in a peer-reviewed journal and presentation at relevant scientific conferences.PROSPERO registration numberCRD42023471315.Strengths and limitations of this studyAssessing the overall impact of COVID-19 vaccines on patients with ITPIncorporating a variety of study types to perform a thorough analysisImplementing a standardized methodology to evaluate and mitigate bias in the studies includedPossible restrictions in data accessibility and variations in heterogeneity among the studies consideredThe effects of different types of COVID-19 vaccines on patients with ITP may differ, leading to potential disparities in the outcomes.

show abstract

Post-COVID-19 hematologic complications: a systematic review

Cited by 11 publications

References 116 publications

Patients with COVID-19 Infection and Stroke have Higher than Expected Mortality, Regardless of the Primary Presentation

Patients with COVID-19 Infection and Stroke have Higher than Expected Mortality, Regardless of the Primary Presentation

Co-Occurring Hemolysis and Methemoglobinemia After COVID-19 Infection in Patient With G6PD Deficiency

The impact of COVID-19 vaccines on patients with immune thrombocytopenic purpura: A protocol for a systematic review and meta-analysis

Contact Info

Product

Resources

About